Novartis reports kidney function benefits for IgAN drug in phase III trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. MH

Go back to Novartis reports kidney function benefits for IgAN drug in phase III trial
NOVARTIS AG (NYSE: NVS) Delayed: 153.39 -0.53 (0.34%)
Previous Close $153.92    52 Week High $89.15 
Open $153.93    52 Week Low $69.84 
Day High $154.22    P/E N/A 
Day Low $153.12    EPS $0.00 
Volume 772,751